Zacks Investment Research lowered shares of Compugen (NASDAQ:CGEN) from a buy rating to a hold rating in a report issued on Monday, January 22nd.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
Separately, ValuEngine lowered Compugen from a sell rating to a strong sell rating in a research report on Sunday, December 31st.
Compugen (CGEN) traded up $0.10 during trading hours on Monday, hitting $3.10. The stock had a trading volume of 140,065 shares, compared to its average volume of 228,581. The company has a market capitalization of $158.90, a PE ratio of -4.37 and a beta of 0.68. Compugen has a 52 week low of $2.25 and a 52 week high of $5.40.
Several large investors have recently added to or reduced their stakes in the business. Paloma Partners Management Co purchased a new position in shares of Compugen during the 4th quarter valued at about $105,000. Virtu Financial LLC purchased a new position in shares of Compugen during the 4th quarter valued at about $162,000. Susquehanna International Group LLP bought a new position in Compugen during the 2nd quarter worth approximately $162,000. Jane Street Group LLC bought a new position in Compugen during the 4th quarter worth approximately $192,000. Finally, Benjamin F. Edwards & Company Inc. grew its position in Compugen by 35.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 85,300 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 22,305 shares during the last quarter. 19.86% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/16/compugen-cgen-cut-to-hold-at-zacks-investment-research.html.
Compugen Company Profile
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Get a free copy of the Zacks research report on Compugen (CGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.